The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Structural basis of PROTAC cooperative recognition for selective protein degradation
Open accessAbstract
Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degradation selectivity remain elusive. We solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4 BD2). The ligand folds into itself to allow formation of specific intermolecular interactions in the ternary complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and proximity assays, are consistent with pronounced cooperative formation of ternary complexes with Brd4 BD2. Structure-based-designed compound AT1 exhibits highly selective depletion of Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, the cooperativity of a bifunctional proximity inducer system is attributable to the ligand-induced protein–protein interface37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“In previous studies of bifunctional proximity inducers, a cooperativity term (represented by α) has been used to characterize the effects of protein–protein interaction in ternary complex formation36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“When plotted on a logarithmic scale, the MG dose-response curve has a familiar sigmoid shape (Fig. 7c), which is in stark contrast to the bell-shaped dose-response curve produced by the bifunctional proximity inducers36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [63]
In the citing paper
“It is widely believed that degraders uncouple efficacy from target occupancy (Gadd et al., 2017; Nowak et al., 2018; Olson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Gadd et al., 2017
In the citing paper
“An essential step in targeted protein degradation is the drug-induced formation of a ternary complex10,43.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [10]
In the citing paper
“While there have been several published crystal structures of ternary complexes 35, 52, 54, there are not yet enough to allow for a thorough and rigorous evaluation of our method.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“The observation that many effective PROTACs exhibit cooperativity in assembling the components of the ternary complex 35, 52, 53 implies the presence of adventitious favorable interactions between the target protein and the E3 ligase in the ternary complex.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“Cooperativity plays a role in the efficiency of the VHL–BRD4 degrader MZ1 (ref.129), but is dispensable for CRBN–BRD4 degraders130.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
CHARMM: The biomolecular simulation program
Brooks, B. R., Brooks, C. L., MacKerell, A. D., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21287 · Cited by 9,115
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Cited by
Sorted by citations
Items 401–500 of 1,001
E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance
Hanzl, A., Barone, E., Bauer, S., Yue, H., Nowak, R. P., Hahn, E., Pankevich, E. V., Koren, A., Kubicek, S., Fischer, E. S., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10784 · Cited by 40
Fan, H., Zhou, Z., Yu, D., Sun, J. F., Wang, L., Jia, Y., Tian, J., Mi, W., & Sun, H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106793 · Cited by 40
Sakaguchi, T., Yoshino, H., Sugita, S., Miyamoto, K., Yonemori, M., Osako, Y., Meguro‐Horike, M., Horike, S., Nakagawa, M., & Enokida, H. (2018) · Oncotarget · doi:10.18632/oncotarget.25190 · Cited by 40
Lu, A. S., Rouhimoghadam, M., Arnatt, C. K., Filardo, E. J., & Salem, A. K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00018 · Cited by 40
Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
Rudolph, J., Settleman, J., & Malek, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0260 · Cited by 42
Shaheer, M., Singh, R., & Sobhia, M. E. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1953601 · Cited by 40
Li, X., Yao, Y., Wu, F., & Song, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01258-8 · Cited by 40
Hu, M., Li, Y., Li, J., Zhou, H., Liu, C., Liu, Z., Gong, Y., Ying, B., & Xie, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114775 · Cited by 40
Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Xiao, Y., Yuan, Y., Liu, Y., Lin, Z., Zheng, G., Zhou, D., & Lv, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00723 · Cited by 39
DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras
Li, F., Hu, Q., Zhou, Y., Yang, H., & Bai, F. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae358 · Cited by 42
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 41
Selective Modulation of Dynamic Protein Complexes
Garlick, J. M., & Mapp, A. K. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.019 · Cited by 39
Native Mass Spectrometry for the Study of PROTAC GNE‐987‐Containing Ternary Complexes
Sternicki, L. M., Nonomiya, J., Liu, M., Mulvihill, M. M., & Quinn, R. J. (2021) · ChemMedChem · doi:10.1002/cmdc.202100113 · Cited by 40
Li, P., Jia, C., Fan, Z., Hu, X., Zhang, W., Liu, K., Sun, S., Guo, H., Yang, N., Zhu, M., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.014 · Cited by 39
Geiger, T. M., Walz, M., Meyners, C., Kuehn, A., Dreizler, J. K., Sugiarto, W. O., Maciel, E. V. S., Zheng, M. J., Lermyte, F., & Hausch, F. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202309706 · Cited by 39
FFLOM: A Flow-Based Autoregressive Model for Fragment-to-Lead Optimization
Jin, J., Wang, D., Shi, G., Bao, J., Wang, J., Zhang, H., Pan, P., Li, D., Yao, X., Liu, H., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01009 · Cited by 38
A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment
Wang, L., Ke, Y., He, Q., Paerhati, P., Zhuang, W., Yue, Y., Liu, J., Zhang, J., Huang, L., Yin, Q., et al. (2024) · Theranostics · doi:10.7150/thno.102531 · Cited by 38
Wu, X., Shu, Y., Zheng, Y., Zhang, P., Cong, H., Zou, Y., Cai, H., & Zha, Z. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081037 · Cited by 39
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38
Pietrobono, S., Gaudio, E., Gagliardi, S., Zitani, M., Carrassa, L., Migliorini, F., Petricci, E., Manetti, F., Makukhin, N., Bond, A. G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01783-9 · Cited by 38
Self-citationWolter, M., Valenti, D., Cossar, P. J., Hristeva, S., Levy, L. M., Genski, T., Hoffmann, T., Brunsveld, L., Tzalis, D., & Ottmann, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00401 · Cited by 38
Designing HDAC-PROTACs: Lessons Learned So Far
Fischer, F., Avelar, L. A. A., Murray, L., & Kurz, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0206 · Cited by 38
Targeting BET Bromodomains in Cancer
Trojer, P. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-103531 · Cited by 38
PROTAC: targeted drug strategy. Principles and limitations
Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 38
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Liu, X., Wang, A., Shi, Y., Dai, M., Liu, M., & Cai, H. (2023) · Molecules · doi:10.3390/molecules28031217 · Cited by 38
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
Hu, Y., Zhao, Y., Li, P., Lu, H., Li, H., & Ge, J. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.07.032 · Cited by 37
New Means and Challenges in the Targeting of BTK
Nawaratne, V., Sondhi, A. K., Abdel-Wahab, O. I., & Taylor, J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0409 · Cited by 37
Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
Kim, K., Lee, D.-H., Park, S., Jo, S.-H., Ku, B., Park, S. G., Park, B. C., Jeon, Y. U., Ahn, S., Kang, C. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56177-5 · Cited by 37
Cell-Based Ligand Discovery for the ENL YEATS Domain
Asiaban, J. N., Milosevich, N., Chen, E., Bishop, T. R., Wang, J. Q., Zhang, Y., Ackerman, C. J., Hampton, E. N., Young, T. S., Hull, M. V., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00124 · Cited by 37
A kinetic proofreading model for bispecific protein degraders
Bartlett, D. W., & Gilbert, A. M. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09722-z · Cited by 38
Discovery of allosteric binding sites by crystallographic fragment screening
Krojer, T. J., Fraser, J. S., & von Delft, F. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.08.004 · Cited by 37
Bemis, T. A., Clair, J. J. L., & Burkart, M. D. (2020) · Chemical Communications · doi:10.1039/d0cc05395c · Cited by 37
A PROTAC targets splicing factor 3B1
Gama-Brambila, R. A., Chen, J., Zhou, J., Tascher, G., Münch, C., & Cheng, X. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.018 · Cited by 37
CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Chen, Y., Cai, Q., Pan, C., Liu, W., Li, L., Liu, J., Gao, M., Li, X., Wang, L., Rao, Y., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0806 · Cited by 37
PROTACs for BRDs proteins in cancer therapy: a review
Wang, C., Zhang, Y., Yang, S., Chen, W., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2081164 · Cited by 37
Self-citationPROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
Madan, J., Ahuja, V. K., Dua, K., Samajdar, S., Ramchandra, M., & Giri, S. (2022) · BioDrugs · doi:10.1007/s40259-022-00551-9 · Cited by 37
Tang, H., Wang, L., Wang, T., Yang, J., Zheng, S., Tong, J., Jiang, S., Zhang, X., & Zhang, K. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115607 · Cited by 37
Chemically induced degradation of epigenetic targets
Kabir, M., Yu, X., Kanıskan, H. Ü., & Jin, J. J. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00100h · Cited by 36
TAC‐tics for Leveraging Proximity Biology in Drug Discovery
Nalawansha, D. A., Mangano, K., den Besten, W., & Potts, P. R. (2023) · ChemBioChem · doi:10.1002/cbic.202300712 · Cited by 36
Mslati, H., Gentile, F., Pandey, M. K., Ban, F., & Cherkasov, A. R. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01878 · Cited by 37
Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm
Nengroo, M. A., Khan, M. A., Verma, A., & Datta, D. B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188790 · Cited by 37
Hu, J., Hu, B., Xu, F., Wang, M., Qin, C., McEachern, D., Stuckey, J. A., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00520 · Cited by 36
An updated patent review of BRD4 degraders
Ma, Z., Zhang, C., Bolinger, A. A., & Zhou, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2400166 · Cited by 35
High-throughput ligand diversification to discover chemical inducers of proximity
Shaum, J. B., Ordoño, M. M. I., Steen, E. A., Wenge, D. V., Cheong, H., Janowski, J., Hunkeler, M., Bilotta, E. M., Rutter, Z. J., Barta, P. A., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02137-2 · Cited by 41
Self-citationBiophysical and structural insight into the USP8/14‐3‐3 interaction
Centorrino, F., Ballone, A., Wolter, M., & Ottmann, C. (2018) · FEBS Letters · doi:10.1002/1873-3468.13017 · Cited by 35
Scaffold hopping enables direct access to more potent PROTACs with in vivo activity
Burslem, G. M., Bondeson, D. P., & Crews, C. M. (2020) · Chemical Communications · doi:10.1039/d0cc02201b · Cited by 35
Frost, J., Rocha, S., & Ciulli, A. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100910 · Cited by 35
Self-citationMacabuag, N., Esmieu, W., Breccia, P., Jarvis, R. E., Blackaby, W., Lazari, O., Urbonas, L., Eznarriaga, M., Williams, R., Strijbosch, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01149 · Cited by 35
Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Salama, A. K. A. A., Trkulja, M. V., Casanova, E., & Uras, I. Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315440 · Cited by 36
Key Considerations in Targeted Protein Degradation Drug Discovery and Development
Qin, L., Dai, H., & Wang, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.934337 · Cited by 35
Malarvannan, M., Unnikrishnan, S., Monohar, S., Ravichandiran, V., & Paul, D. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107984 · Cited by 34
Stevens, R., Shrives, H. J., Cryan, J., Klimaszewska, D., Stacey, P., Burley, G. A., Harling, J. D., Battersby, D. J., & Miah, A. H. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00760c · Cited by 34
The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells
Wolf, G., Craigon, C., Teoh, S. T., Essletzbichler, P., Onstein, S., Cassidy, D. M., Uijttewaal, E. C. H., Dvorak, V., Cao, Y., Bensimon, A., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2024.11.009 · Cited by 34
Self-citationMacrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV
Newton, L. S., Gathmann, C., Ridewood, S., Smith, R. J., Wijaya, A. J., Hornsby, T. W., Morling, K. L., Davison, D., Chiozzi, R. Z., Reuschl, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56317-8 · Cited by 34
Self-citationMethods to accelerate PROTAC drug discovery
Osman, J., Thompson, P. E., Jörg, M., & Scanlon, M. J. (2025) · Biochemical Journal · doi:10.1042/bcj20243018 · Cited by 34
Schiedel, M., Moroglu, M., Ascough, D. M. H., Chamberlain, A. E. R., Kamps, J. J. A. G., Sekirnik, A. R., & Conway, S. J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812164 · Cited by 34
Hughes, G. R., Dudey, A. P., Hemmings, A. M., & Chantry, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.010 · Cited by 34
Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms
Wang, Q., Shao, X., Leung, E. L., Chen, Y., & Yao, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105804 · Cited by 34
Structure‐Based Design of a Macrocyclic PROTAC
Testa, A., Hughes, S. J., Lucas, X., Wright, J. E., & Ciulli, A. (2019) · Angewandte Chemie · doi:10.1002/ange.201914396 · Cited by 34
Self-citationA comprehensive review of BET-targeting PROTACs for cancer therapy
Zhou, X., Zhao, F., Xu, Y.-T., Guan, Y., Yu, T., Zhang, Y., Duan, Y., & Zhao, Y. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117033 · Cited by 36
Targeted Protein Degradation: Design Considerations for PROTAC Development
Tran, N. L., Leconte, G. A., & Ferguson, F. M. (2022) · Current Protocols · doi:10.1002/cpz1.611 · Cited by 35
Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets
Bulatov, E., Zagidullin, A. A., Valiullina, A., Sayarova, R., & Rizvanov, A. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00450 · Cited by 34
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
Protein degraders - from thalidomide to new PROTACs
Ito, T. (2023) · The Journal of Biochemistry · doi:10.1093/jb/mvad113 · Cited by 33
Grifagni, D., Lenci, E., Santis, A. D., Orsetti, A., Barracchia, C. G., Tedesco, F., Puglielli, R. B., Lucarelli, F., Lauriola, A., Assfalg, M., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00498 · Cited by 33
A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach
Chou, C.-L., Lin, C., Kao, C., & Lin, C. (2024) · ACS Omega · doi:10.1021/acsomega.3c10183 · Cited by 33
Balzarini, M., Tong, J., Gui, W., Jayalath, I. M., Schell, B.-B., & Kodadek, T. J. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00422 · Cited by 33
Fu, Y., Liu, Y., Yi, K., Li, M., Li, J., & Ye, F. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00556 · Cited by 33
Yokoo, H., Shibata, N., Endo, A., Ito, T., Yanase, Y., Murakami, Y., Fujii, K., Hamamura, K., Saeki, Y., Naito, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01206 · Cited by 33
Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
He, S., Gao, F., Ma, J., Ma, H., Dong, G., & Sheng, C. (2021) · Angewandte Chemie · doi:10.1002/ange.202107347 · Cited by 33
E3 ligase autoinhibition by C-degron mimicry maintains C-degron substrate fidelity
Scott, D. C., King, M. T., Baek, K., Gee, C. T., Kalathur, R., Li, J., Purser, N., Nourse, A., Chai, S. C., Vaithiyalingam, S., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.019 · Cited by 33
Chaudhry, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02076 · Cited by 35
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
Wang, C., Zhang, Y., Chen, W., Wang, Y., & Xing, D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188927 · Cited by 34
Self-citationKoo, T.-Y., Lai, H., Nomura, D. K., & Chung, C. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39268-w · Cited by 35
A comprehensive review of emerging approaches in machine learning for de novo PROTAC design
Gharbi, Y., & Mercado, R. (2024) · Digital Discovery · doi:10.1039/d4dd00177j · Cited by 32
PROTACs technology for targeting non-oncoproteins: Advances and perspectives
Wang, C., Zhang, Y., Xing, D., & Zhang, R. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105109 · Cited by 32
Lim, Y. S., Yoo, S.-M., Patil, V., Kim, H. W., Kim, H.-H., Suh, B., Park, J. Y., Jeong, N.-R., Park, C. H., Ryu, J. H., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008121 · Cited by 32
Rational Prediction of PROTAC-Compatible Protein–Protein Interfaces by Molecular Docking
Pereira, G. P., Jiménez‐García, B., Pellarin, R., Launay, G., Wu, S., Martin, J., & Souza, P. C. T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01154 · Cited by 32
Could PROTACs Protect Us From COVID-19?
Martinez‐Ortiz, W., & Zhou, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.08.007 · Cited by 32
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 31
Song, J. H., Wagner, N. D., Yan, J. R., Li, J., Huang, R. Y. ‐., Balog, A., Newitt, J. A., Chen, G., & Gross, M. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.005 · Cited by 31
Liang, Y., Fang, R., & Rao, Q. (2022) · Molecules · doi:10.3390/molecules27092837 · Cited by 31
Molecular glues: enhanced protein-protein interactions and cell proteome editing
Weagel, E. G., Foulks, J. M., Siddiqui, A. Q., & Warner, S. L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02882-2 · Cited by 31
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Activity-based profiling of cullin–RING E3 networks by conformation-specific probes
Henneberg, L. T., Singh, J., Duda, D. M., Baek, K., Yanishevski, D., Murray, P. J., Mann, M., Sidhu, S. S., & Schulman, B. A. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01392-5 · Cited by 31
Makukhin, N., & Ciulli, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00272k · Cited by 31
Self-citationUnifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms
Rodriguez-Rivera, F. P., & Levi, S. M. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00389 · Cited by 30
Gunasekaran, P., Hwang, Y. S., Lee, G., Park, J., Kim, J. G., La, Y. K., Park, N. Y., Kothandaraman, R., Yim, M. S., Choi, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01493 · Cited by 30
He, T., Cheng, C., Qiao, Y., Cho, H., YOUNG, E. A., Mannan, R., Mahapatra, S., Miner, S. J., Zheng, Y., Kim, N. H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322563121 · Cited by 30
Schwalm, M. P., Saxena, K., Müller, S., & Knapp, S. (2024) · Nature Protocols · doi:10.1038/s41596-024-00979-z · Cited by 33
Zhu, H., Gao, F., Li, Y., Jiang, M., Zhang, Y., Chen, K., Han, L., Xue, S., Wang, K., Fan, Q., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102308 · Cited by 30
Intrinsic signaling pathways modulate targeted protein degradation
Yuki, M., Akizuki, Y., Honda, R., Takao, M., Tsuchimoto, A., Hashimoto, S., Iio, H., Kato, M., Kaiho-Soma, A., Saeki, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49519-z · Cited by 30
Protein degradation: a validated therapeutic strategy with exciting prospects
Lebraud, H., & Heightman, T. D. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170030 · Cited by 30
Targeting epigenetic reader domains by chemical biology
Cipriano, A., Sbardella, G., & Ciulli, A. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.05.006 · Cited by 30
Self-citationRiching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787 · Cited by 30
A covalent BTK ternary complex compatible with targeted protein degradation
Schiemer, J. S., Maxwell, A., Horst, R., Liu, S., Uccello, D. P., Borzilleri, K. A., Rajamohan, N., Brown, M. F., & Calabrese, M. F. (2023) · Nature Communications · doi:10.1038/s41467-023-36738-z · Cited by 30
Fiorentino, F., Rotili, D., & Mai, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103548 · Cited by 30
ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling
Liu, C., Armstrong, C. M., Ning, S., Yang, J. C., Lou, W., Lombard, A. P., Zhao, J., Wu, C., Yu, A., Evans, C. P., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01914-2 · Cited by 30
Metadata
- Authors
- Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Ciulli, Alessio
- Venue
- Nature Chemical Biology
- Published
- 2017-03-13
- Volume
- 13
- Issue
- 5
- Pages
- 514-521
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5392356
- OpenAlex
- W2597078857
- Cited by
- 1,242
- References
- 60
- Citations by year
- 2026: 173 · 2025: 173 · 2024: 176 · 2023: 159 · 2022: 138 · 2021: 129 · 2020: 133 · 2019: 86 · 2018: 46 · 2017: 26
- FWCI
- 33.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 100476/Z/12/Z)
- Diamond Light Source (MX10071)
- European Commission (H2020-MSCA-IF-2014, H2020- MSCA-IF-2015, H2020, 655516, H2020‐MSCA‐IF, H2020-MSCA)
- Directorate for Biological Sciences
- Horizon 2020 Framework Programme (H2020‐MSCAIF‐2014, H2020-MSCA, MSCA-IF-2014, H2020-MSCA-IF-2015)
- Medical Research Council
- Biotechnology and Biological Sciences Research Council (BB/J001201/1, BB/J001201/2)
- H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2014, H2020-MSCA-IF-2014-655516, H2020, 655516, H2020-MSCA-IF, H2020-MSCA-IF-2015, H2020-MSCA, 806323, H2020-MSCA-IF-2015-806323)
- FP7 Ideas: European Research Council (311460)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, BRD4, VHL E3 ubiquitin ligase, bromodomain, selective protein degradation, crystal structure, ternary complex, structure-based drug design, ubiquitination
- MeSH terms
- Elongin, Bromodomain Containing Proteins, Amino Acid Sequence, Dipeptides, Heterocyclic Compounds, 3-Ring, Humans, Models, Molecular, Nuclear Proteins, Protein Binding, Protein Conformation, Structure-Activity Relationship, Thermodynamics, Transcription Factors, Crystallography, X-Ray, Cell Cycle Proteins, Ubiquitin-Protein Ligases, Multiprotein Complexes, Von Hippel-Lindau Tumor Suppressor Protein, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
